Volmex Global Licenses Volatility Indices to Bitfinex Derivatives
The BVIVF0:USTF0 and EVIVF0:USTF0 perpetual futures contracts launched on Bitfinex Derivatives track the 30-day expected volatility of Bitcoin and Ether options per the Volmex Implied Volatility Indices methodology. Both contracts can be traded with up to 20 times leverage.
Volmex Labs is the creator of the Volmex Implied Volatility Indices, the BVIV Index (Bitcoin Volmex Implied Volatility), and the EVIV Index (Ethereum Volmex Implied Volatility) - the first and leading crypto volatility indices. Volmex Implied Volatility Index data is available on leading platforms, including TradingView and CoinMarketCap.
To access BVIVF0:USTF0 and EVIVF0:USTF0 on Bitfinex Derivatives, eligible customers can visit https://www.bitfinex.com.
About Volmex
Volmex Global is a wholly-owned subsidiary of Volmex Labs, the creator of the leading crypto volatility indices, the BVIV (Bitcoin Volmex Implied Volatility) and EVIV (Ethereum Volmex Implied Volatility) Indices. The BVIV and EVIV Indices measure the constant, forward-looking 30-day expected volatility of BTC and ETH, respectively, derived from real-time crypto call and put options. Volmex Implied Volatility Index data is available on leading platforms, including TradingView and CoinMarketCap. Visit https://volmex.finance to learn more and https://charts.volmex.finance to access the Volmex Implied Volatility Indices.
About Bitfinex Derivatives
Launched in
View original content:https://www.prnewswire.com/news-releases/volmex-global-licenses-volatility-indices-to-bitfinex-derivatives-302107154.html
SOURCE Volmex Global
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agentic AI Foundation Launches MCPA Certification to Validate MCP Expertise
- Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
- Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Options, BitcoinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share